Eyenovia Inc (EYEN) Prices 4.39M Share Common Stock Offering at $2.78/Share

Eyenovia, Inc. (NASDAQ: EYEN), a clinical stage ophthalmic biopharmaceutical company developing a pipeline of microdose therapeutics utilizing its patented piezo-print technology, today announced the pricing of an underwritten public offering of 4,388,490 shares of its common stock at a price to the public of $2.78 per share. In addition, Eyenovia has granted the underwriters a 30-day option to purchase up to 658,273 additional shares of common stock at the public offering price, less underwriting discounts and commissions. The offering is expected to close on July 15, 2019, subject to customary closing conditions.

The gross proceeds to Eyenovia from the public offering, before deducting underwriting discounts and commissions and offering expenses payable by Eyenovia, are expected to be approximately $12.2 million. Eyenovia intends to use the net proceeds from the public offering, together with other available funds, for the MicroProst and MicroPine clinical studies and for working capital and general corporate purposes.

Oppenheimer & Co. Inc. is acting as the sole book-running manager for the offering. Ladenburg Thalmann & Co. Inc. is acting as the lead manager for the offering. National Securities Corporation is acting as the co-manager for the offering.

You May Also Be Interested In

• Bimegren Energy (BESS) files $100M mixed shelf
• ADARx Pharmaceuticals prices $446.3M IPO at $17 per share
• Forward Industries raises $25M in stock offering to buy Solana